TagsOncology 
TARGRETIN™

TARGRETIN™ (bexarotene) MAIN LIFE HK Reg. No. HK-68294 (04 Jul, 2024) Composition: 1 Targretin™ (bexarotene) is a member of a subclass of retinoids that selectively activate retinoid X receptors (RXRs). Targretin™ is available in c...

Aug 20, 2024
The Unmet Needs in Relapse/ Refractory Multiple Myeloma: A Clinical Challenge

Multiple myeloma (MM) is a haematologic malignancy characterised by abnormal clonal plasma cells in the bone marrow with a potential for uncontrolled growth causing destruction, osseous lesion, acute kidney injury (AKI), anaemia, and hypercalcaemia....

Aug 20, 2024
Overcoming the TP53 Mutated AML Treatment Dilemma

Tumour protein 53 (TP53) gene is located on the chromosome 17 that encodes for the p53 protein, which is a tumour suppressor protein with 393 amino acid responsible for regulating cellular stress 1 . Notably, TP53 can be inactivated directly due to ...

Apr 18, 2024
The Ever-Changing Landscape of Unresectable Hepatocellular Carcinoma

Paradigm Shift in Management of Unresectable Hepatocellular Carcinoma (uHCC) In Hong Kong, liver cancer is the fifth most common cancer (with 1,771 new cases of liver cancer reported in 2021) and the third most common cause of cancer-related deaths ...

Apr 18, 2024
Taking a New Approach to Dyslipidaemia

Early Insight to the Dyslipidaemia Pandemic Dyslipidaemia is defined as lipid imbalance affecting the low high-density lipoprotein cholesterol (HDL-C), elevated triglyceride (TG), high low-density lipoprotein cholesterol (LDL-C) and elevated total c...

Feb 8, 2024
EXKIVITY

EXKIVITY (mobocertinib) TAKEDA Indications: EXKIVITY is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, ...

Feb 6, 2024
COLUMVI

COLUMVI (glofitamab-gxbm) ROCHE Indications: COLUMVI is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from foll...

Feb 6, 2024
Ground-breaking Delivery of Anti-cancer Drug Against Lymph Node Metastasis

Being spotted in multiple cancer types, lymph node (LN) metastasis literally is the symbol of dreadful patient outcomes, characterizing poor prognosis and shorter survival. Recent research has highlighted sentinel LNs as the gateway for haematogenou...

Feb 6, 2024
Turning RCC to Rejoice, Courage, and Care: A Review on the Management of Renal Cell Carcinoma and the Related Innovations

Renal cell carcinomas (RCCs) are the most common type of kidney cancer in adults and is prevalent in adult male aged between 60 and 70. Notably, clear cell RCC (ccRCC) is the most abundant subtype of RCC with the worse disease-specific survival as i...

Feb 6, 2024
Trodelvy

Trodelvy (sacituzumab govitecan) Gilead Presentation: Each vial contains 180 mg of Sacituzumab govitecan. Off-white to yellowish lyophilized powder in a single-dose vial. Indications: Trodelvy is indicated for the treatment of adult patients wit...

Dec 18, 2023
Exkivity

Exkivity® ( mobocertinib ) 1-3 Takeda Mobocertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that selectively inhibits and irreversibly binds to EGFR exon 20 insertion mutations at lower concentrations than Wild type (...

Jun 13, 2023